JAK2-negative ET patients do not display constitutively active JAK/STAT signaling

Sven Schwemmers(University of Freiburg), Heike L. Pahl(University Medical Center Freiburg), Khadija Abdulkarim(Sahlgrenska University Hospital), Britta Will(Albert Einstein College of Medicine), Peter Johansson(Linköping University), Björn Andréasson(NU Hospital Group), Cornelius F. Waller(University Medical Center Freiburg)

Experimental Hematology

August 31, 2007

10.1016/j.exphem.2007.07.004

Cited by 35

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

|Leukemia|2012|417

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

|Leukemia|2017|339

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

|Journal of Clinical Oncology|2013|299